207 related articles for article (PubMed ID: 24192532)
1. The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
Bloom AJ; von Weymarn LB; Martinez M; Bierut LJ; Goate A; Murphy SE
Pharmacogenet Genomics; 2013 Dec; 23(12):706-16. PubMed ID: 24192532
[TBL] [Abstract][Full Text] [Related]
2. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
3. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Bloom J; Hinrichs AL; Wang JC; von Weymarn LB; Kharasch ED; Bierut LJ; Goate A; Murphy SE
Pharmacogenet Genomics; 2011 Jul; 21(7):403-16. PubMed ID: 21597399
[TBL] [Abstract][Full Text] [Related]
4. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
Berg JZ; Mason J; Boettcher AJ; Hatsukami DK; Murphy SE
J Pharmacol Exp Ther; 2010 Jan; 332(1):202-9. PubMed ID: 19786624
[TBL] [Abstract][Full Text] [Related]
5. Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
Murphy SE; Sipe CJ; Choi K; Raddatz LM; Koopmeiners JS; Donny EC; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1093-1099. PubMed ID: 28264876
[No Abstract] [Full Text] [Related]
6. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
Berg JZ; von Weymarn LB; Thompson EA; Wickham KM; Weisensel NA; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1423-31. PubMed ID: 20501767
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M; Yokoi T
Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
[TBL] [Abstract][Full Text] [Related]
8. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.
Wassenaar CA; Conti DV; Das S; Chen P; Cook EH; Ratain MJ; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):94-104. PubMed ID: 25277794
[TBL] [Abstract][Full Text] [Related]
9. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.
Taghavi T; St Helen G; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2017 Apr; 27(4):143-154. PubMed ID: 28178031
[TBL] [Abstract][Full Text] [Related]
10. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
Chen G; Giambrone NE; Dluzen DF; Muscat JE; Berg A; Gallagher CJ; Lazarus P
Cancer Res; 2010 Oct; 70(19):7543-52. PubMed ID: 20876810
[TBL] [Abstract][Full Text] [Related]
11. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
12. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.
Murphy SE; Park SS; Thompson EF; Wilkens LR; Patel Y; Stram DO; Le Marchand L
Carcinogenesis; 2014 Nov; 35(11):2526-33. PubMed ID: 25233931
[TBL] [Abstract][Full Text] [Related]
13. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.
Chen G; Blevins-Primeau AS; Dellinger RW; Muscat JE; Lazarus P
Cancer Res; 2007 Oct; 67(19):9024-9. PubMed ID: 17909004
[TBL] [Abstract][Full Text] [Related]
14. The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations.
Patel YM; Stram DO; Wilkens LR; Park SS; Henderson BE; Le Marchand L; Haiman CA; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):119-27. PubMed ID: 25293881
[TBL] [Abstract][Full Text] [Related]
15.
Sipe CJ; Koopmeiners JS; Donny EC; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1673-1678. PubMed ID: 32532831
[TBL] [Abstract][Full Text] [Related]
16. Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers.
Murphy SE; von Weymarn LB; Parenteau M; Stepanov I; Tiirikainen M; LeMarchand L; Park SL
Chem Res Toxicol; 2018 Mar; 31(3):168-175. PubMed ID: 29460622
[TBL] [Abstract][Full Text] [Related]
17. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10.
Kaivosaari S; Toivonen P; Hesse LM; Koskinen M; Court MH; Finel M
Mol Pharmacol; 2007 Sep; 72(3):761-8. PubMed ID: 17576790
[TBL] [Abstract][Full Text] [Related]
18. Relationship between cotinine and trans-3'-hydroxycotinine glucuronidation and the nicotine metabolite ratio in Caucasian smokers.
Jacobson GA; Ferguson SG
Biomarkers; 2014 Dec; 19(8):679-83. PubMed ID: 25373622
[TBL] [Abstract][Full Text] [Related]
19. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G; Giambrone NE; Lazarus P
Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
[TBL] [Abstract][Full Text] [Related]
20. Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.
Murphy SE
Chem Res Toxicol; 2017 Jan; 30(1):410-419. PubMed ID: 28092945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
